These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3037289)

  • 21. Herpes vaccine.
    Mindel A
    Br J Vener Dis; 1984 Jun; 60(3):204-5. PubMed ID: 6329408
    [No Abstract]   [Full Text] [Related]  

  • 22. Seventeen years of application of herpes vaccines in Bulgaria.
    Dundarov S; Andonov P
    Acta Virol; 1994 Aug; 38(4):205-8. PubMed ID: 7879710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs.
    Welch MJ; Ridgeway PH; Phillpotts RJ
    FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of type 2 herpes simplex virus induced cervical carcinoma in mice by prior immunization with a vaccine prepared from type 1 herpes simplex virus.
    Chen MH; Dong CY; Liu ZH; Skinner GR; Hartley CE
    Vaccine; 1983 Dec; 1(1):13-6. PubMed ID: 6099637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for control of herpes simplex virus disease through immunization.
    Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ
    Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
    Berman PW; Gregory T; Crase D; Lasky LA
    Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A virus-particle vaccine prepared from bovine mammillitis virus against herpes genitalis.
    Skinner GR; Buchan A; Davies J; Durham J; Castrucci G
    Comp Immunol Microbiol Infect Dis; 1991; 14(2):133-50. PubMed ID: 1657508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genital herpes.
    Nilsen A
    Scand J Infect Dis Suppl; 1985; 47():51-7. PubMed ID: 3006234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New concepts: vaccines.
    Rapp F
    Gynecol Oncol; 1981 Oct; 12(2 Pt 2):S341-4. PubMed ID: 6273265
    [No Abstract]   [Full Text] [Related]  

  • 31. Serological assessment of acyclovir treatment of herpes genitalis.
    Ragab NF; Habib MA; Ghozzi MY
    Arch Androl; 1989; 23(2):147-53. PubMed ID: 2556084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. College students' attitudes regarding vaccination to prevent genital herpes.
    Rosenthal SL; Lewis LM; Succop PA; Bernstein DI; Stanberry LR
    Sex Transm Dis; 1999 Sep; 26(8):438-43. PubMed ID: 10494934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunologic strategies for herpes vaccination.
    Hartley C
    JAMA; 2000 Feb; 283(6):746; author reply 746-7. PubMed ID: 10683052
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection.
    Erturk M; Phillpotts RJ; Welch MJ; Jennings R
    Vaccine; 1991 Oct; 9(10):728-34. PubMed ID: 1661978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunologic strategies for herpes vaccination.
    Friedman HM
    JAMA; 2000 Feb; 283(6):746; author reply 746-7. PubMed ID: 10683051
    [No Abstract]   [Full Text] [Related]  

  • 36. [Indices of the immune status of recurrent herpes patients being treated with a herpes polyvaccine].
    Belokrinitskiĭ DV; Karpovich LG; Barinskiĭ IF; Bukovskaia SN; Semenova TB
    Vopr Virusol; 1987; 32(2):229-33. PubMed ID: 3037800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modification of the genital herpes infection in a guinea pig model, by prior immunization with bovine herpes mammillitis virus.
    Maragos C; May JT
    Microbiol Immunol; 1988; 32(5):547-50. PubMed ID: 2845232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender-specific predictors of genital herpes vaccine acceptance in a college population.
    Auslander BA; Rosenthal SL; Succop PA; Mills LM; Stanberry LR; Bernstein DI
    Int J STD AIDS; 2005 Jan; 16(1):27-30. PubMed ID: 15705269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
    Ashley RL; Crisostomo FM; Doss M; Sekulovich RE; Burke RL; Shaughnessy M; Corey L; Polissar NL; Langenberg AG
    J Infect Dis; 1998 Jul; 178(1):1-7. PubMed ID: 9652416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.
    Skinner GR; Buchan A; Williams D; Marsden J; Hartley C; Wilbanks G; Turyk M; Namkoong ES
    Br J Exp Pathol; 1982 Aug; 63(4):378-87. PubMed ID: 6295430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.